Tab%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520linagliptin

# Linagliptin ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon secretion. Unlike other DPP-4 inhibitors, it is primarily excreted via the hepatobiliary system rather than renal elimination. ## Primary Indications Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ## Adult Dosing 5 mg orally once daily. May be taken with or without food. ## Pediatric Dosing Safety and efficacy have not been established in pediatric patients. Use is generally not recommended. ## Dose Adjustments **Renal Impairment:** No dose adjustment is required regardless of the degree of renal impairment (including end-stage renal disease). **Hepatic Impairment:** No dose adjustment is required. ## Contraindications * History of hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions). * Type 1 diabetes or treatment of diabetic ketoacidosis. ## Adverse Effects * **Common:** Nasopharyngitis, hypoglycemia (when used with insulin or secretagogues). * **Serious:** Acute pancreatitis (discontinue if suspected), severe and disabling arthralgia, bullous pemphigoid (requires medical attention), and hypersensitivity reactions. ## Key Drug Interactions * **Strong CYP3A4/P-gp Inducers (e.g., rifampin):** May decrease linagliptin efficacy. Avoid co-administration. * **Insulin/Insulin Secretagogues (e.g., sulfonylureas):** Increased risk of hypoglycemia; a lower dose of the secretagogue may be required. ## Monitoring * **Glycemic control:** HbA1c (typically every 3 to 6 months) and periodic fingerstick glucose monitoring. * **Pancreatitis:** Monitor for persistent, severe abdominal pain. * **Hypersensitivity:** Monitor for skin rashes, blistering, or signs of angioedema. ## Clinical Pearls * **Non-Renal Clearance:** Linagliptin is unique among DPP-4 inhibitors as its primary route of elimination is fecal (biliary), making it a preferred choice for patients with significant renal impairment. * **Weight Neutrality:** Linagliptin is weight-neutral and carries a low risk of hypoglycemia when used as monotherapy. * **Missed Dose:** Take as soon as remembered, but do not take two doses on the same day. *** **Educational Disclaimer:** This information is for educational purposes only. Always consult current, full prescribing information (package insert) and institutional clinical protocols before prescribing or administering medication. Clinical practice is subject to change based on new evidence.